Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, BidAskClub reports.

Several other research firms have also recently commented on ATRA. Evercore ISI started coverage on Atara Biotherapeutics in a report on Tuesday, June 30th. They issued an “outperform” rating for the company. Mizuho started coverage on Atara Biotherapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $38.00 price target for the company. HC Wainwright started coverage on Atara Biotherapeutics in a report on Monday, June 15th. They issued a “buy” rating and a $25.00 price target for the company. Citigroup upgraded Atara Biotherapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price target for the company in a report on Thursday, April 23rd. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a report on Tuesday, July 21st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $27.60.

Atara Biotherapeutics stock traded down $0.64 during midday trading on Thursday, reaching $12.39. 1,038,033 shares of the company were exchanged, compared to its average volume of 746,260. The firm’s 50-day simple moving average is $13.07 and its 200-day simple moving average is $11.62. Atara Biotherapeutics has a 1 year low of $4.52 and a 1 year high of $19.36. The company has a current ratio of 7.27, a quick ratio of 7.27 and a debt-to-equity ratio of 0.05.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($1.20) EPS for the quarter, beating the consensus estimate of ($1.41) by $0.21. Equities research analysts predict that Atara Biotherapeutics will post -4.53 earnings per share for the current fiscal year.

In related news, CEO Pascal Touchon sold 12,135 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $12.92, for a total transaction of $156,784.20. Following the transaction, the chief executive officer now directly owns 264,844 shares of the company’s stock, valued at approximately $3,421,784.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.30% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Atara Biotherapeutics by 66.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,485 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,786 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Atara Biotherapeutics in the 1st quarter valued at approximately $284,000. Victory Capital Management Inc. raised its position in shares of Atara Biotherapeutics by 31.3% in the 4th quarter. Victory Capital Management Inc. now owns 10,384 shares of the biotechnology company’s stock valued at $171,000 after purchasing an additional 2,473 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Atara Biotherapeutics by 35.8% in the 1st quarter. SG Americas Securities LLC now owns 10,828 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 2,855 shares in the last quarter. Finally, Arizona State Retirement System acquired a new position in shares of Atara Biotherapeutics in the 1st quarter valued at approximately $97,000.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Further Reading: Oversold

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.